BioStock: CombiGene's new agreement important for future clinical studies

The Gene therapy company CombiGene announced yesterday that an agreement has been signed with CDMO manufacturer Cobra Biologics, regarding GMP production of two of the essential plasmids needed for the production of the company’s drug candidate CG01. In doing so, the company is taking a step closer to clinical studies with CG01 and a future treatment for drug-resistant focal epilepsy. 

Read the full article about CombiGene at biostock.se:

https://www.biostock.se/en/combigenes-new-agreement-important-for-future-clinical-studies/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/